Data Insights

FP-020 by Foresee Pharmaceuticals for Sarcoidosis: Likelihood of Approval

FP-020 is under clinical development by Foresee Pharmaceuticals and currently in Phase I for Sarcoidosis. According to GlobalData, Phase I...

Likelihood of Approval and Phase Transition Success Rate Model - FP-020 in Sarcoidosis

Data Insights

Aderamastat by Foresee Pharmaceuticals for Sarcoidosis: Likelihood of Approval

Aderamastat is under clinical development by Foresee Pharmaceuticals and currently in Phase I for Sarcoidosis. According to GlobalData, Phase I...

Likelihood of Approval and Phase Transition Success Rate Model - Aderamastat in Sarcoidosis

Data Insights

FP-045 by Foresee Pharmaceuticals for Fanconi Anemia: Likelihood of Approval

FP-045 is under clinical development by Foresee Pharmaceuticals and currently in Phase II for Fanconi Anemia. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - FP-045 in Fanconi Anemia

Data Insights

FP-045 by Foresee Pharmaceuticals for Pulmonary Arterial Hypertension: Likelihood of Approval

FP-045 is under clinical development by Foresee Pharmaceuticals and currently in Phase I for Pulmonary Arterial Hypertension. According to GlobalData,...

Data Insights

FP-045 by Foresee Pharmaceuticals for Fanconi Anemia: Likelihood of Approval

FP-045 is under clinical development by Foresee Pharmaceuticals and currently in Phase II for Fanconi Anemia. According to GlobalData, Phase...

Data Insights

Leuprorelin SR by Foresee Pharmaceuticals for Central Precocious Puberty: Likelihood of Approval

Leuprorelin SR is under clinical development by Foresee Pharmaceuticals and currently in Phase III for Central Precocious Puberty. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Leuprorelin SR in Central Precocious Puberty